Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1) Journal Article
| Authors: | Perez, M. C.; Zager, J. S.; Amatruda, T.; Conry, R.; Ariyan, C.; Desais, A.; Kirkwood, J. M.; Treichel, S.; Cohan, D.; Raskin, L. |
| Article Title: | Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1) |
| Abstract: | Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials & methods: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible. Results: Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported. Conclusion: T-VEC was well tolerated and showed clinical utility. |
| Keywords: | melanoma; immunotherapy; oncolytic virus; combination therapy; metastatic melanoma; t-vec; talimogene; real-world evidence; tvec; laherparepvec |
| Journal Title: | Melanoma Management |
| Volume: | 6 |
| Issue: | 2 |
| ISSN: | 2045-0885 |
| Publisher: | Future Medicine |
| Date Published: | 2019-06-01 |
| Start Page: | MMT19 |
| Language: | English |
| ACCESSION: | WOS:000484235700003 |
| DOI: | 10.2217/mmt-2019-0012 |
| PROVIDER: | wos |
| PMCID: | PMC6688558 |
| PUBMED: | 31406563 |
| Notes: | Article -- Source: Wos |
